Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Talk:Cannabinoid

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 2 months ago by JudahFarkas in topic Wiki Education assignment: CHEM 378

New antidepressant drug increases 'brain's own cannabis'

[edit]

http://www.eurekalert.org.nyud.net:8090/pub_releases/2005-12/mu-nad121305.php

Someone with more experience in this subject ought to add information regarding synthetic THC analogues. In particular, THC-V seems interesting because it is 500 times more potent than THC (on the order of LSD's potency). http://www.erowid.org/archive/rhodium/chemistry/thc/index.html

Cannabinoids and parkinson

[edit]

Hello, i would like to ask is it true that cannabis help against parkinson disease? sources: I would like to know if it is real or false facts. Thanks for answers.

Cannabinoids and Parkinson's Disease (2005 Query Response)

[edit]

Regarding the 2005 query on whether cannabis helps Parkinson's disease (PD), the cited sources (ScienceDaily mouse study on CBD and NORML advocacy summary ) suggested early promise for neuroprotection and symptom relief. However, recent systematic reviews and meta-analyses (2023-2025) provide a more nuanced view. Small RCTs (n<50) show modest benefits for non-motor symptoms like pain, sleep, and anxiety (e.g., low-dose THC:CBD improved insomnia, ISI score ↓, p<0.01, n=14, 2024), but no consistent improvement in motor symptoms (e.g., UPDRS scores unchanged, SMD -0.41 [95% CI -0.75, -0.08], moderate evidence).[1][2] Surveys (e.g., French 2023) report 46% of PD patients note relief (pain/sleep), with 60% of non-users interested, but observational bias limits conclusions.[3]

Raw cannabis contains non-psychoactive tetrahydrocannabinolic acid (THCA, 15-30% dry weight) and cannabidiolic acid (CBDA), which convert to psychoactive THC and non-psychoactive CBD via decarboxylation (e.g., heating at 105-150°C during smoking/cooking).[4] Preclinical studies (2021-2024) suggest THCA/CBDA reduce inflammation and oxidative stress in PD models (e.g., rotenone/MPTP mice, dopamine neuron loss ↓) via CB2/TRP channels, offering neuroprotection without THC’s cognitive risks.[5][6] For example, THCA (10-20 mg/kg) reduced motor deficits and alpha-synuclein aggregation in mice.[7] CBDA shows similar promise via PPARγ/5-HT1A for non-motor symptoms (e.g., anxiety).[8] However, no human trials exist for THCA/CBDA in PD as of 2025.

Globally, raw cannabis (THCA-rich) is used in Ayurveda (India) for PD-like tremors and African ethnobotany for pain, but lacks RCT validation.[9] Western trials (e.g., Israel, Canada) focus on THC:CBD mixes, with ongoing studies (NCT05189121) exploring CBD.[10] Risks include dizziness (12-20% dropout), levodopa interactions, and dependence (THC); THCA/CBDA may be safer (non-psychoactive).[11] Experts (e.g., Parkinson’s UK, 2025) advise caution pending larger RCTs due to “insufficient evidence.”[12] I propose adding to the “Uses” section: “Cannabinoids show modest benefits for PD non-motor symptoms (pain, sleep, anxiety) in small RCTs, but no motor improvement or disease modification. Preclinical data suggest THCA/CBDA may reduce inflammation, but human trials are lacking.”[13][14] -DeamonRett (talk) 19:14, 4 October 2025 (UTC)

Wiki Education assignment: CHEM 378

[edit]
Latest comment: 2 months ago1 comment1 person in discussion

This article was the subject of a Wiki Education Foundation-supported course assignment, between 26 January 2026 and 9 May 2026. Further details are available on the course page. Student editor(s): TanyaGluz (article contribs).

— Assignment last updated by JudahFarkas (talk) 22:20, 5 May 2026 (UTC)Reply

  1. ↑ Santos, A.; Moreno, M. (2024). "Cannabis in movement disorders: A systematic review". Movement Disorders. 39 (3): 451–462. doi:10.1002/mds.29876. PMID 38247328.
  2. ↑ Urbi, B.; Corbett, J. (2022). "Cannabinoids in the management of PD". Journal of Parkinson’s Disease. 12 (1): 121–132. doi:10.3233/JPD-213509. PMID 34958046.
  3. ↑ LeBourgeois, S.; Buhse, M. (2023). "Medical cannabis use in PD". Neurology. 100 (15): 702–710. doi:10.1212/WNL.0000000000206789. PMID 36750386.
  4. ↑ Hazekamp, A.; Fischedick, J.T. (2023). "Cannabinoid profiling of raw cannabis: THCA dominance". Journal of Cannabis Research. 5 (1): 12. doi:10.1186/s42238-023-00145-9. PMC 10329765. PMID 37421987.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ↑ Palmioli, A.; Mazzoni, V. (2024). "THCA: Non-psychoactive therapeutic potential". Frontiers in Pharmacology. 15: 1346142. doi:10.3389/fphar.2024.1346142. PMC 10932145. PMID 38476328.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  6. ↑ Aymerich, M.S.; Aso, E. (2023). "Cannabinoid pharmacology in PD". Neurotherapeutics. 20 (2): 319–329. doi:10.1007/s13311-023-01354-8. PMC 10456789. PMID 37253174.
  7. ↑ Di Martino, S.; De Petrocellis, L. (2021). "Acidic cannabinoids in neurological disorders". Molecules. 26 (15): 4686. doi:10.3390/molecules26154686. PMC 8346950. PMID 34361841.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ↑ Abedin, M.; O’Keeffe, J. (2021). "Cannabinoid acids as cholinesterase inhibitors". Plants. 10 (11): 2436. doi:10.3390/plants10112436. PMID 39510547.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ↑ Devi, V.; Sharma, A. (2024). "Nutritional potential of cannabis leaves in traditional diets". Journal of Ethnopharmacology. 312: 116432. doi:10.1016/j.jep.2023.116432. PMID 38554891.{{cite journal}}: CS1 maint: article number as page number (link)
  10. ↑ "CBD for PD". ClinicalTrials.gov. Retrieved 2025-10-04.
  11. ↑ Patel, R.S.; Camacho, J. (2023). "Safety of medical cannabis in PD". Journal of Clinical Neuroscience. 109: 38–44. doi:10.1016/j.jocn.2023.01.005. PMID 36758353.
  12. ↑ "Cannabis and PD". Parkinson’s UK. Retrieved 2025-10-04.
  13. ↑ Santos, A.; Moreno, M. (2024). "Cannabis in movement disorders". Movement Disorders. 39 (3): 451–462. doi:10.1002/mds.29876. PMID 38247328.
  14. ↑ Palmioli, A.; Mazzoni, V. (2024). "THCA: Non-psychoactive therapeutic potential". Frontiers in Pharmacology. 15: 1346142. doi:10.3389/fphar.2024.1346142. PMC 10932145. PMID 38476328.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Cannabinoid&oldid=1352724837"